UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 27, 2017
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| Delaware | | 001-33038 | | 84-1475642 |
(State or Other Jurisdiction of Incorporation) | | (Commission
File Number) | | (IRS Employer Identification No.) |
| | |
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts | | 02129 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(617)259-1970
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if theForm 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act(17 CFR 240.14a-12). |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)). |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)). |
| Item 7.01 | Regulation FD Disclosure |
On March 27, 2017, ZIOPHARM Oncology, Inc., or the Company, issued a press release announcing the receipt of positive guidance from anEnd-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy product candidate,Ad-RTS-hIL-12 plus orally administered veledimex (V), to harness and controlIL-12 production for the investigational treatment of recurrent glioblastoma (GBM), an aggressive form of brain cancer with few treatment options.
The information contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company’s filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.
| Item 9.01 | FinancialStatementsandExhibits |
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press Release dated March 27, 2017 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | ZIOPHARM Oncology, Inc. |
| | | |
| | | | By: | | /s/ Kevin G. Lafond |
| Date: March 27, 2017 | | | | | | Name: | | Kevin G. Lafond |
| | | | | | Title: | | Senior Vice President, Chief Accounting Officer and Treasurer |
3
INDEX OF EXHIBITS
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press Release dated March 27, 2017 |
4
